Publication: Diagnostic biomarkers of differentiated thyroid cancer
3
Issued Date
2012-12-01
Resource Type
ISSN
15590100
1355008X
1355008X
Other identifier(s)
2-s2.0-84890786203
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Endocrine. Vol.44, No.3 (2012), 616-622
Suggested Citation
Tada Kunavisarut Diagnostic biomarkers of differentiated thyroid cancer. Endocrine. Vol.44, No.3 (2012), 616-622. doi:10.1007/s12020-013-9974-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/13562
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Diagnostic biomarkers of differentiated thyroid cancer
Author(s)
Other Contributor(s)
Abstract
The incidence of thyroid cancer has been increasing all around the world in the past decades. Early detection is one of the keys to reduce the mortality. Currently, fine-needle aspiration (FNA) guides the management of patients with a thyroid nodule. The use of FNA can reduce unnecessary thyroid surgery by twenty-five percent. However, the prevalence of non-diagnostic and indeterminate cytology from FNA is still high, approximately thirty percent. Many biomarkers were developed to differentiate between the benign and malignant thyroid nodule. This review summarizes each diagnostic biomarker of differentiated thyroid cancer. Sensitivity, specificity, and positive and negative predictive values of individual cytological laboratory need to be considered before implementation of each biomarker. Moreover, follow-up is still mandatory in negative biomarker tests because all genomic and proteomic alterations in thyroid cancer are still unknown. © 2013 Springer Science+Business Media New York.